255051-14-0

Basic information

• Product Name: 4-(2-(TRIFLUOROMETHYL)PHENYL)PIPERIDINE HYDROCHLORIDE
• Synonyms: 4-(2-(TRIFLUOROMETHYL)PHENYL)PIPERIDINE HYDROCHLORIDE
• CAS NO: 255051-14-0
• Molecular Formula: C₁₂H₁₄F₃N*ClH
• Molecular Weight: 265.7
• Mol File: 255051-14-0.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 305.1 °C at 760 mmHg
• Flash Point: 138.3 °C
• Appearance: /
• Vapor Pressure: 0.000626mmHg at 25°C
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 4-(2-(TRIFLUOROMETHYL)PHENYL)PIPERIDINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-(TRIFLUOROMETHYL)PHENYL)PIPERIDINE HYDROCHLORIDE(255051-14-0)
• EPA Substance Registry System: 4-(2-(TRIFLUOROMETHYL)PHENYL)PIPERIDINE HYDROCHLORIDE(255051-14-0)

Safety Data

• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 255051-14-0(Hazardous Substances Data)

Usage

General Description

4-(2-(Trifluoromethyl)phenyl)piperidine hydrochloride is a chemical compound that belongs to the class of piperidine derivatives. It is a hydrochloride salt form of a piperidine compound with a trifluoromethyl-substituted phenyl group. This chemical is widely used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. It has potential applications in the field of medicinal chemistry, particularly in the development of new drugs for treating central nervous system disorders and psychiatric conditions. Additionally, it may also be used in the synthesis of other organic compounds for research and development purposes.

InChI:InChI=1/C12H14F3N.ClH/c13-12(14,15)11-4-2-1-3-10(11)9-5-7-16-8-6-9;/h1-4,9,16H,5-8H2;1H

Upstream product

• 821768-10-9 1-benzyl-4-(2-(trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyridine 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 308823-90-7 4-(2-(trifluoromethyl)phenyl)piperidine 
• 392-83-6 o-trifluoromethylphenyl bromide 
• 1370256-36-2 C₁₉H₁₈F₃N*ClH 
• 208989-32-6 1-benzyl-4-hydroxy-4-(2-tri-fluoromethylphenyl)piperidine 

Relevant articles and documents

Design, Synthesis, and Preclinical Efficacy of Novel Nonretinoid Antagonists of Retinol-Binding Protein 4 in the Mouse Model of Hepatic Steatosis

Retinol-binding protein 4 (RBP4) serves as a transporter for all-trans-retinol (1) in the blood, and it has been proposed to act as an adipokine. Elevated plasma levels of the protein have been linked to diabetes, obesity, cardiovascular diseases, and nonalcoholic fatty liver disease (NAFLD). Recently, adipocyte-specific overexpression of RBP4 was reported to cause hepatic steatosis in mice. We previously identified an orally bioavailable RBP4 antagonist that significantly lowered RBP4 serum levels in Abca4-/- knockout mice with concomitant normalization of complement system protein expression and reduction of bisretinoid formation within the retinal pigment epithelium. We describe herein the discovery of novel RBP4 antagonists 48 and 59, which reduce serum RBP4 levels by >80% in mice upon acute oral dosing. Furthermore, 59 demonstrated efficacy in the transgenic adi-hRBP4 murine model of hepatic steatosis, suggesting that RBP4 antagonists may also have therapeutic utility for the treatment of NAFLD.

4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE

The present invention provides a compound having the structure: (structurally represented) wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl; R6 is H, OH, or halogen; B is a substituted or unsubstituted heterobicycle, pyridazine, pyrazole, pyrazine, thiadiazole, or triazole, wherein the heterobicycle is other than chloro substituted indole; and the pyrazole, when substituted, is substituted with other than trifluoromethyl, or a pharmaceutically acceptable salt theref.

Synthesis and SAR study of 4-arylpiperidines and 4-aryl-1,2,3,6- tetrahydropyridines as 5-HT2C agonists

A series of substituted 4-arylpiperidines and a smaller family of 4-aryl-1,2,3,6-tetrahydropyridines were synthesized and their biological activity at the 5-HT2C receptor studied to determine whether either series showed noteworthy agonist activity. Structure-activity relationships were developed from the performed receptor binding assays and functional studies, and the results of the analysis are presented herein.